KOSDAQBiotech & Pharma095700

Genexine

₩1,817▼ 3.66%2026-11-18 close
Market Cap
₩82.7B
Turnover
₩200M
Volume
110K
Shares out.
45.5M
PER
—
PBR
0.5×
EPS
-₩1,459
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Litigation cleared, losses and funding remain the test

Genexine's final arbitration win in April 2026 removed a claim of about KRW 200 billion, but four consecutive years of operating losses and short-term borrowing pressure remain the key variables.

  1. 1

    In the April 2026 ICC arbitration, all claims by ICHOR Medical Systems were dismissed in a single-instance award, closing a long-running legal overhang.

  2. 2

    On the disclosed figures, the 2025 operating loss was KRW 36.2 billion, a fourth straight loss year since 2022, while Q3 2026 sales rose to KRW 4.16 billion, a second consecutive quarterly increase, with an operating loss of KRW 7.06 billion still recorded.

  3. 3

    Reporting in April 2026 put short-term borrowings at KRW 93.1 billion, above cash and equivalents, and in October 2026 a KRW 3 billion third-party rights issue was withdrawn after the allottee failed to pay.

  4. 4

    On the licensing side, a milestone of USD 3 million (about KRW 4.2 billion) tied to completing a Phase 2 study of GX-I7 was disclosed in August 2026, and a clinical supply deal with Roche for a GX-I7 combination study was announced in October 2026.

  5. 5

    The bioPROTAC pipeline is at the IND-package and preclinical-data stage for GX-BP1, and the company has set a target of at least one licensing deal within 2026.

02

Business structure

Genexine's core asset is GX-I7 (efineptakin alfa), a long-acting interleukin-7 immuno-oncology candidate, and the company also develops biobetter products built on its long-acting hyFc platform.

GX-E4, an anemia treatment, and GX-H9, a growth hormone therapy for growth hormone deficiency, are reported to be in Phase 3 trials on the company website. The China launch timing for GX-H9 has been pushed back several times, from 2024 to 2025 and then to 2026, via its Chinese partner.

In a Phase 2 study of GX-I7 in recurrent glioblastoma, progression-free and overall survival did not show statistically significant differences versus historical controls, as reported in February 2025. GX-I7 is now being advanced through combination studies with MSD's pembrolizumab and Roche's bevacizumab.

In 2026 the bioPROTAC platform, which uses targeted protein degradation, became a new pillar.

GX-BP1 for lung cancer, GX-BP2 for atopic dermatitis, and GX-BP3 for spinocerebellar ataxia are in preclinical or proof-of-concept stages, and preclinical combination data for GX-BP1 were presented at the World Conference on Lung Cancer in September 2026.

Revenue appears to be driven by lumpy receipts such as licensing fees and milestones, and the company's Magok R&D center received its occupancy approval in January 2026.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩3B-₩7.4B−243.6%
2025Q4₩500M-₩12.8B−2379.5%
2026Q1₩400M-₩9B−2170.0%
2026Q2₩1B-₩10.5B−1079.6%
2026Q3₩4.2B-₩7.1B−169.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩16.1B-₩33.7B-₩56.8B−208.7%−20.8%40.2%
2023₩4.4B-₩41.2B-₩66.9B−931.7%−22.5%26.8%
2024₩2.9B-₩37.2B-₩63.7B−1270.0%−24.3%31.9%
2025₩4.6B-₩36.2B-₩27.2B−790.8%−11.0%50.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

On the disclosed annual figures, sales fell from KRW 16.1 billion in 2022 to KRW 4.43 billion in 2023, a 72.6% decline year on year, and to KRW 2.93 billion in 2024, down 33.7%. Sales recovered to KRW 4.57 billion in 2025, up 56.0% year on year. 2022 was the largest year of the four and 2024 the smallest.

Operating losses were KRW 33.7 billion in 2022, KRW 41.2 billion in 2023, KRW 37.2 billion in 2024 and KRW 36.2 billion in 2025, a loss in each of the four years. The operating margin moved from -208.7% in 2022 to -931.7% in 2023 and -1,270.0% in 2024, then improved to -790.8% in 2025.

The attributable net loss was KRW 56.8 billion, KRW 66.9 billion, KRW 63.7 billion and KRW 27.2 billion for 2022 through 2025, and the total net loss figures match these values. Operating cash flow was negative in every year, at -KRW 39.8 billion, -KRW 38.1 billion, -KRW 1.65 billion and -KRW 29.6 billion.

The debt ratio rose from 31.9% in 2024 to 50.5% in 2025, with total equity of KRW 246.8 billion at year-end 2025.

On a quarterly basis, sales were KRW 3.05 billion in Q3 2025, KRW 537 million in Q4 2025, KRW 415 million in Q1 2026, KRW 972 million in Q2 2026 and KRW 4.16 billion in Q3 2026, the last two quarters both increasing.

Operating losses over the same stretch were KRW 7.42 billion, KRW 12.8 billion, KRW 9 billion, KRW 10.5 billion and KRW 7.06 billion. Q3 2025 recorded an attributable net profit of KRW 21.1 billion despite an operating loss, which points to non-operating items driving the gap. Over the four quarters from Q4 2025 to Q3 2026, the attributable net loss totaled KRW 66.4 billion.

05

Industry analysis

In the bio-pharma sector, immuno-oncology development has shifted toward combinations with checkpoint inhibitors rather than stand-alone use. Genexine's clinical work with MSD's pembrolizumab and Roche's bevacizumab follows that path.

Combination studies, however, depend on partners' drug supply and trial design, and they become business value only when results are positive. The glioblastoma Phase 2 result, which did not clear statistical thresholds, illustrates how high the clinical bar is in this area.

Targeted protein degradation has expanded as researchers seek to address the off-target toxicity limits of small-molecule PROTACs, and the company argues that its nanobody-based binders can reach proteins that small molecules cannot bind.

Because clinical data for this modality are still limited, large pharma partners often ask for clinical evidence before licensing. Peers frequently compared with Genexine include Hanmi Pharm, Yuhan, Alteogen, ABL Bio and Peptron.

Genexine runs three axes at once, long-acting protein platforms, immuno-oncology and protein degradation, so its risk profile differs from that of a company with a single commercialized product.

06

Outlook

The most concrete business goal the company has set is licensing of its bioPROTAC pipeline. In late 2025 co-CEO Choi Jae-hyun first targeted a licensing deal in the first half of 2026, then adjusted the target to at least one deal within 2026.

GX-BP1 has completed animal studies and built its IND package, and the company said it would begin substantive talks with global partners once it has the raw data from GLP toxicity studies. GX-BP2, being developed for atopic dermatitis, was expected in February 2026 to enter preclinical development in Q4 2026.

Timelines for existing programs have repeatedly slipped. The expected Korean approval timing for GX-E4 moved from 2025 Q2 to 2026 Q2–Q3 or later, and the China launch of GX-H9 was adjusted to 2026. Given this pattern, the company's outlook should be confirmed quarter by quarter through its filings.

The company disclosed in August 2026 that it would receive a USD 3 million milestone for completing a Phase 2 study of GX-I7 licensed to its affiliate and licensee, and in October 2026 it signed a Roche supply agreement for a glioblastoma combination study.

Further GX-I7 milestones and the scope of combination studies will depend on the clinical results. With the arbitration concluded in April 2026, the company said it could focus more on its core pipeline and global business expansion.

07

Valuation

PER
—
PBR
0.5×
ROE
-30.5%
EPS
-₩1,459
BPS
₩3,855
Dividend per share
₩0

Because the net loss over the last four quarters totals KRW 66.4 billion, a price-to-earnings ratio cannot be calculated on current earnings. The price-to-book ratio sits below 1x, meaning market capitalization is below book equity.

Total equity was KRW 246.8 billion at year-end 2025 against total liabilities of KRW 124.5 billion, so the balance sheet still has some room.

However, operating cash flow has been negative every year, and short-term borrowings exceeded cash and equivalents as reported in April 2026, so book equity does not translate directly into cash. The company pays no dividend, so a comparison based on dividend yield does not apply.

A price below book value can be read as the market pricing in continuing operating losses, while the arbitration closure and licensing revenue could narrow that gap. Which reading proves right depends on the size of future losses and how funding is secured. A comparison with the historical band of the multiple requires a review of past multiples over time.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Legal overhang removed

In the April 2026 ICC arbitration, all claims by ICHOR Medical Systems, about KRW 200 billion, were dismissed, and the single-instance award cannot be reheard. The company's legal costs are also borne by the other side. Removing this contingent liability takes one major uncertainty out of the balance-sheet assessment.

Licensing income becoming visible

The August 2026 disclosure said a USD 3 million milestone tied to the Phase 2 completion of GX-I7 was confirmed and due within 30 days. Q3 2026 sales of KRW 4.16 billion rose sharply from the prior quarter, and sales increased in two consecutive quarters. This shows that contract receipts can lift reported revenue.

bioPROTAC pipeline expanding

GX-BP1 has completed animal studies and built an IND package for Phase 1 entry, and preclinical combination data for lung cancer were presented in September 2026. The company expects GX-BP2 to enter preclinical development in Q4 2026.

If the protein-degradation platform wins licensing interest, the business options expand regardless of current revenue scale.

09

Bear factors

Four straight years of operating losses

On disclosed figures, operating losses ran from KRW 33.7 billion in 2022 to KRW 36.2 billion in 2025, four straight loss years. The 2025 operating margin of -790.8% improved from -1,270.0% in 2024, but losses did not disappear.

The attributable net loss over the last four quarters totals KRW 66.4 billion, so a clear earnings recovery is not yet visible.

Borrowings and cash outflows

Reporting in April 2026 put short-term borrowings at KRW 93.1 billion, above cash and equivalents, with KRW 77.8 billion linked to facility financing. Operating cash flow was -KRW 29.6 billion in 2025. In October 2026, a KRW 3 billion third-party rights issue was withdrawn after the allottee failed to pay.

Recurring delays and clinical setbacks

A Phase 2 study of GX-I7 in recurrent glioblastoma did not reach statistical significance for progression-free or overall survival, as announced in February 2025. The expected approval timing for GX-E4 in Korea has been pushed back several times, and the China launch of GX-H9 moved from 2024 to 2026. The licensing target for bioPROTAC programs has also shifted from the first half of 2026 to year-end.

10

Risk factors

Funding

Short-term borrowings and facility-related debt coincide with continuing operating cash outflows, which may require additional funding. The withdrawn October 2026 rights issue suggests the financing route may be limited. Any capital raise could dilute existing shareholders.

Development timing and trial results

The results of GX-I7 combination studies and the clinical entry timing for GX-BP1 and GX-BP2 are central to the business. The company has repeatedly moved its timelines, so whether targets are met should be checked each quarter. Weak clinical data could also weaken negotiating positions in licensing talks.

Lumpy, one-off revenue

Quarterly sales swing widely, from KRW 3.05 billion in Q3 2025 to KRW 537 million in Q4 2025. The Q3 2026 increase appears to reflect milestone receipts, so whether such income recurs is an open question. If one-off receipts do not repeat, the underlying loss structure would become more visible.

11

What to watch next

  1. Late December 2026

    Whether a bioPROTAC licensing deal is signed. The company targeted at least one deal within 2026, and its upfront and milestone terms would set the baseline for future revenue.

  2. Q4 2026

    Whether GX-BP2 enters preclinical development. Entry into this stage would indicate the pace of the bioPROTAC pipeline.

  3. Late March 2027

    Release of the 2026 annual report. It will confirm full-year operating loss, attributable net loss, operating cash flow, borrowings and the debt ratio, replacing provisional quarterly figures with audited data.

  4. Mid-May 2027

    Q1 2027 quarterly report. It will show how year-end 2026 borrowings are reflected in quarterly profit and cash flow.

12

Overall view

Genexine cleared its largest legal uncertainty in April 2026, when ICHOR Medical Systems' claim of about KRW 200 billion was dismissed in a final single-instance award.

On the licensing side, the August 2026 GX-I7 milestone disclosure and the October 2026 Roche supply agreement for a combination study were announced, and Q3 2026 sales of KRW 4.16 billion marked a second consecutive quarterly increase.

However, on the disclosed figures, operating losses have run for four straight years from 2022 through 2025, and the attributable net loss over the last four quarters totals KRW 66.4 billion. Short-term borrowings, negative operating cash flow and the withdrawn October 2026 rights issue remain funding challenges.

The pipeline has clear checkpoints, including GX-I7 combination studies, bioPROTAC licensing and GX-BP2's entry into preclinical development. The company's history of repeated timeline slips means each target should be checked quarter by quarter.

The strengths, namely the resolved legal overhang and visible licensing income, and the weaknesses, namely prolonged losses and borrowing pressure, are presented here with equal weight.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. paxetv.com
  2. thebionews.net
  3. edaily.co.kr
  4. edaily.co.kr
  5. bosa.co.kr
  6. edaily.co.kr
  7. pharm.edaily.co.kr
  8. genexine.com
  9. genexine.com
  10. newstomato.com
  11. hankyung.com
  12. v.daum.net
  13. v.daum.net
  14. cbci.co.kr
  15. anewsa.com
  16. seo.goover.ai
  17. pharm.edaily.co.kr
  18. v.daum.net

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis